- NASDAQ:IMMU rose for the second straight day after nearly doubling in price.
- Gilead shares remained flat on Tuesday after rising by 3% after the deal was announced.
NASDAQ:IMMU continued its upward rise towards the acquisition price of $88 per share that Gilead Sciences (NASDAQ:GILD) has agreed to pay for the biotech firm based out of New Jersey. Shares climbed a further 1.32% on Tuesday closing the trading session at $84.75 – which is down from briefly touching at all-time high prices of $86.91. IMMU stock is now up nearly 890% over the last 52-weeks compared to the 12.57% growth of the S&P 500. Of course, much of this has been enhanced by yesterday’s surge, so the true number pre-acquisition was still up nearly 380%.
Gilead investors seemed slightly more apprehensive about the deal, despite openly urging the pharmaceutical giant to start spending some of its large cash reserves. Before the deal to acquire Immunomedics, Gilead was sitting on about $30 billion in cash and had not made an acquisition since its 2017 purchase of Kite Pharma – a deal that probably did not turn out as lucrative as Gilead had hoped. The deal for Immunomedics cements Gilead's position in the oncology market and provides them with a tumour treatment that the behemoth was sorely missing. Trodelvy is Gilead’s first foray into breast cancer tumours as the other two treatments they have, Yescarta and Tecartus, are for treating blood cancers.
IMMU stock news
IMMU investors are still riding high after Monday’s jump and the fact that the stock continued to rise on Tuesday shows that not many are taking their profits and leaving. Trodelvy will provide an estimated $3-4 billion a year for Gilead, so the steep price that they did pay for Immunomedics should prove to pay itself off within a few years.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
EUR/USD bounces off lows, retests 1.1370
Following an early drop to the vicinity of 1.1310, EUR/USD now manages to regain pace and retargets the 1.1370-1.1380 band on the back of a tepid knee-jerk in the US Dollar, always amid growing optimism over a potential de-escalation in the US-China trade war.
GBP/USD trades slightly on the defensive in the low-1.3300s
GBP/USD remains under a mild selling pressure just above 1.3300 on Friday, despite firmer-than-expected UK Retail Sales. The pair is weighed down by a renewed buying interest in the Greenback, bolstered by fresh headlines suggesting a softening in the rhetoric surrounding the US-China trade conflict.
Gold remains offered below $3,300
Gold reversed Thursday’s rebound and slipped toward the $3,260 area per troy ounce at the end of the week in response to further improvement in the market sentiment, which was in turn underpinned by hopes of positive developments around the US-China trade crisis.
Ethereum: Accumulation addresses grab 1.11 million ETH as bullish momentum rises
Ethereum saw a 1% decline on Friday as sellers dominated exchange activity in the past 24 hours. Despite the recent selling, increased inflows into accumulation addresses and declining net taker volume show a gradual return of bullish momentum.
Week ahead: US GDP, inflation and jobs in focus amid tariff mess – BoJ meets
Barrage of US data to shed light on US economy as tariff war heats up. GDP, PCE inflation and nonfarm payrolls reports to headline the week. Bank of Japan to hold rates but may downgrade growth outlook. Eurozone and Australian CPI also on the agenda, Canadians go to the polls.
The Best brokers to trade EUR/USD
SPONSORED Discover the top brokers for trading EUR/USD in 2025. Our list features brokers with competitive spreads, fast execution, and powerful platforms. Whether you're a beginner or an expert, find the right partner to navigate the dynamic Forex market.